Compare ARQT & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQT | AAPG |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.9B |
| IPO Year | 2020 | 2025 |
| Metric | ARQT | AAPG |
|---|---|---|
| Price | $29.51 | $30.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $24.83 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 2.3M | 4.5K |
| Earning Date | 10-28-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $317,929,000.00 | $54,524,554.00 |
| Revenue This Year | $85.51 | N/A |
| Revenue Next Year | $30.74 | $368.64 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.21 | N/A |
| 52 Week Low | $11.13 | $16.50 |
| 52 Week High | $31.77 | $48.45 |
| Indicator | ARQT | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 59.80 | 41.81 |
| Support Level | $28.95 | $30.00 |
| Resistance Level | $31.77 | $32.96 |
| Average True Range (ATR) | 1.36 | 0.93 |
| MACD | -0.14 | 0.07 |
| Stochastic Oscillator | 54.51 | 46.92 |
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.